IP Library Patent Application 15343689
Patent Application
App. No. 15/343,689

PHARMACEUTICAL COMPOSITIONS COMPRISING DGLA AND USE OF SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/343,689
Abstract

The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.

Claims (20)

1 . A method of treating atopic dermatitis in a human subject, the method comprising administering to the subject daily a pharmaceutical composition comprising 600 mg to 5000 mg of dihomo gamma linolenic acid.

2 . The method of claim 1 wherein the pharmaceutical composition is present in one or more capsules.

3 . The method of claim 2 wherein each of the one or more capsules comprises 500 mg to about 1 g of the pharmaceutical composition.

4 . The method of claim 1 wherein two capsules each comprising about 1 g of the pharmaceutical composition are administered to the subject per day.

5 . The method of claim 1 wherein four capsules each comprising about 1 g of composition are administered to the subject per day.

6 . The method of claim 1 wherein the dihomo gamma linolenic acid comprises at least about 80% by weight of total fatty acids present in the pharmaceutical composition.

7 . The method of claim 1 wherein said administering effects an increase in plasma total DGLA of at least about 10% in the subject.

8 . The method of claim 1 wherein the pharmaceutical composition further comprises eicosatrienoic acid and eicosadienoic acid.

9 . A method of treating atopic dermatitis in a human subject, the method comprising administering daily to the subject a pharmaceutical composition comprising dihomo gamma linolenic acid, eicosatrienoic acid and eicosadienoic acid, wherein the dihomo gamma linolenic acid comprises at least about 80% by weight of all fatty acids in the composition and the pharmaceutical composition is administered in an amount effective to deliver 600 mg to 5000 mg of dihomo gamma linolenic acid to the subject per day.

10 . The method of claim 9 wherein the composition is present in one or more capsules.

11 . The method of claim 10 wherein each of the one or more capsules comprises about 500 mg to about 1 g of the composition.

12 . The method of claim 10 wherein two capsules each comprising about 1 g of the composition are administered to the subject per day.

13 . The method of claim 10 wherein four capsules each comprising up to about 1 g of the composition are administered to the subject per day.

14 . The method of claim 9 where said administering effects an increase in plasma total DGLA of at least about 10% in the subject.

15 . A method of treating atopic dermatitis in a human subject, the method comprising administering to the subject a pharmaceutical composition comprising dihomo gamma linolenic acid, arachidonic acid, eicosatrienoic acid and eicosadienoic acid, wherein the dihomo gamma linolenic acid comprises at least about 80% by weight of all fatty acids in the pharmaceutical composition and the pharmaceutical composition is administered in an amount effective to deliver 600 mg to 5000 mg of dihomo gamma linolenic acid to the subject per day.

16 . The method of claim 15 wherein the composition is present in one or more capsules.

17 . The method of claim 16 wherein each of the one or more capsules comprises about 500 mg to about 1 g of the composition.

18 . The method of claim 15 wherein two capsules each comprising about 1 g of the composition are administered to the subject per day.

19 . The method of claim 15 wherein four capsules each comprising up to about 1 g of the composition are administered to the subject per day.

20 . The method of claim 15 where said administering effects an increase in plasma total DGLA of at least about 10% in the subject.

Assignments (3)
CHANGE OF NAME Recorded Jul 31, 2017
From: DIGNITY SCIENCES LIMITED
To: DS BIOPHARMA LIMITED
Reel/Frame 043147/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: MANKU, MEHAR; CLIMAX, JOHN; COUGHLAN, DAVID; DUNNE, JAMES
To: DIGNITY SCIENCES LIMITED
Reel/Frame 040279/0912 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2016
From: MANKU, MEHAR; CLIMAX, JOHN; DUNNE, JAMES; COUGHLAN, DAVID
To: DIGNITY SCIENCES LIMITED
Reel/Frame 040226/0932 →